Novel Data On PV-10 For Melanoma Treatment Presented At ASCO

On June 4, 2014 Provectus Pharmaceuticals reported new findings on PV-10, an investigational intra-lesional therapy for melanoma, were presented during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s Annual Meeting on May 31, 2015, Chicago, Illinois, USA (Press release, Provectus Pharmaceuticals, JUN 4, 2015, View Source [SID:1234505231]). The presentation entitled "A Changing Topography: The Role of Intralesional Therapy in Melanoma" was presented by Dr. Sanjiv Agarwala, from St. Luke’s Cancer Center in Bethlehem and Temple University School of Medicine in Pennsylvania, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Melanoma is a cancer that has its origins in melanocytes, cells that produce the brown pigment called melanin which protects the deeper layers of the skin from the harmful effects of the sun. Melanoma is much less frequent than basal cell and squamous cell skin cancers, but it is far more dangerous. Like basal cell and squamous cell cancers, melanoma is almost always curable if detected earlier but has a higher probability to spread to other parts of the body if it is not detected early.

PV-10 is Provectus Biopharmaceuticals’ new experimental drug for cancer, and was designed to be injected into solid tumors i.e. intralesional administration, to reduce potential systemic adverse effects. The FDA has already granted an orphan drug designation for Provectus’ melanoma and hepatocellular carcinoma indications.

Dr. Sanjiv Agarwala established as mains goals of intra-lesional therapy local disease control (decreasing tumor size during a prolonged period), control of symptoms and palliation, decreased systemic effect (immune mediated), delay or prevention of systemic treatment and neo-adjuvant potential. The researcher showed results from the phase 3 trial from T-VEC, an HSV-1-derived oncolytic immunotherapy conceived to induce local and systemic effects. He also showed phase 2 findings for PV-10, showing the drug accumulated within cancer cells but not normal cells, inducing acute autophagy and exposing antigenic tumor fragments to antigenic presenting cells (APCs).

Dr. Agarwala stated that intralesional approaches may hold a promising value, since they act locally and do not have a systemic immune effect. Moreover the researcher concluded that combination therapies are probably the future of melanoma treatment and may be the best way to transition into clinical practice.

Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting

On June 4, 2015 Cellectis reported that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in two oral presentations and one poster presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Meeting (Press release, Cellectis, JUN 4, 2015, View Source [SID:1234505236]). The meeting will be held from June 11th to 14th, 2015, in Vienna, Austria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The selected presentations are as follow:

Allogeneic adoptive immunotherapy of acute myeloid leukemia (ALM) by targeting CD123 with CAR T-Cells
Oral Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination

Presentation Time: Saturday, June 13th, 2015, 12:15pm to 12:30pm

UCART19, an Allogeneic "Off-the-Shelf" Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias
Oral Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination

Presentation Time: Saturday, June 13th, 2015, 12:30pm to 12:45pm

Adoptive immunotherapy of multiple myeloma (MM) with allogeneic CAR T-Cells targeting CS1: enhancement of CAR activity through CS1 gene inactivation in effector cells
Poster Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination Presentation Time: Saturday, June 13th, 2015, 5:15pm to 6:45pm

Navidea to Report Manocept™ Results in Kaposi’s Sarcoma at the International Workshop on KSHV and Related Agents

On June 4, 2015 Navidea Biopharmaceuticals reported that four presentations of Manocept data from Kaposi’s Sarcoma (KS) studies are scheduled at the 18th International Workshop on Kaposi’s Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida from June 30 – July 3, 2015 (Press release, Navidea Biopharmaceuticals, JUN 4, 2015, View Source;p=RssLanding&cat=news&id=2056585 [SID:1234505429]). This research highlights a very likely new approach to the origin of KS supported by preclinical and clinical imaging studies. In addition, data will be presented demonstrating the therapeutic potential for Manocept therapeutic conjugates. MT1001 is a proprietary agent designed to target cells expressing the mannose receptor (CD206) and destroy the cell and its contents. Data will be presented demonstrating MT1001’s ability to target KS and KS tumor-associated macrophages by selectively binding to CD206. Details of the presentations are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session:

Date: July 1, 2015
Title: In Vivo Localization and Potential for Therapeutic Targeting of Kaposi’s Sarcoma (KS) With A Novel CD206 Localizing Agent
Authors: M McGratha,b*, J Zhanga, T Maurera, S Behra, B Abbruzzesec, J Sandersc, P Braccia,b, FO Copec (*Presenter)

aUniv of California-San Francisco; bAIDS & Cancer Specimen Resource, SFGH c Navidea/Macrophage Therapeutics

Poster Session:

Date: July 1, 2015

Title: Imaging and Therapeutic Potential for Kaposi’s Sarcoma (KS) In Non-Cutaneous Foci with a Novel CD206 Localizing Agent

Authors: B Abbruzzesea*, FO Copea, J Zhangb, T Maurerb, S Behrb, J Sandersa, P Braccib,c, M McGrathb,c (*Presenter)

aNavidea/Macrophage Therapeutics; bUniv of California-San Francisco; cAIDS & Cancer Specimen Resource, SFGH

Poster Session:

Date: July 1, 2015

Title: Kaposi’s Sarcoma (KS) is a Macrophage (MO) Tumor Resulting from a Fusion CD206+MOs and Lymphatic Endothelium

Authors: FO Copea*, J Zhangb, T Maurerb, B Abbruzzesea, J Sandersa, S Behrb, P Braccib,c, M McGrathb,c (*Presenter)

aNavidea/Macrophage Therapeutics; bUniv of California-San Francisco; cAIDS & Cancer Specimen Resource, SFGH

Oral Session: Translational Studies. KSHV Malignancies Associated with HIV/AIDS

Date: July 2, 2015
Title: Manocept, a Novel CD206 Targeting Agent for Potential Use in Treatment of Kaposi’s Sarcoma

Authors: Rongzhen Zhanga, Frederick O. Copeb, Joshua Walkerc, Ken Williamsc, Ekaterina Maidjia, Cheryl Stoddarta, Paige M. Braccia, Michael S. McGratha* (*Presenter)

aUniversity of California San Francisco; bNavidea/Macrophage Therapeutics; cBoston College

Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East

On June 3, 2015 Varian Medical Systems reported Varian Medical Systems is expanding in the Middle East with the creation of a strategic operating entity in Saudi Arabia. Varian Medical Systems Arabia, the result of a joint venture with El Seif Development Group, was officially launched today at a ceremony attended by local dignitaries and Varian’s chief executive officer Dow Wilson (Press release, InfiMed, JUN 3, 2015, View Source [SID:1234505221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This move represents the next step in our commitment both to cancer patients and the medical community in Saudi Arabia," said Dow Wilson. "Radiotherapy plays a vital and cost effective role in treating cancer and we are committed to making more advanced treatment systems available to more patients across the region."

Varian Medical Systems Arabia will be home to 35 sales, service and administrative employees supporting Varian’s three business segments: Oncology Systems, Imaging Components and Particle Therapy. Varian has also established a spare parts depot in Riyadh.

"We look forward to supporting the ministry of health in Saudi Arabia as well as with the other healthcare service providers in the military sector, independent organizations and private hospitals," said Mazyad Al Utaibi, managing director of VMS Arabia. "Our expertise, experience, strengths and capabilities ensure we are well placed to continue offering our partners the latest technology and local service to fight cancer and help save lives."

Varian is the leading provider of radiotherapy systems to Saudi hospitals. The first Varian linear accelerator was installed in Saudi Arabia over 30 years ago and the company now has 22 systems operating across the country. Varian was also selected to equip the Middle East’s first proton therapy center, which is under construction at King Fahad Medical City in Riyadh.

AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib

On June 3, 2015 AVEO Oncology reported that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application (Press release, AVEO, JUN 3, 2015, View Source;p=RssLanding&cat=news&id=2056290 [SID:1234505227]). The Rapporteur (from Portugal) and Co-Rapporteur (from the United Kingdom) are the two appointed members of the Committee for Medicinal Products for Human Use (CHMP) who would lead the evaluation of the MAA, if submitted.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application would be based on the Company’s existing dataset, which includes results from the Phase 3 TIVO-1 study of tivozanib in the first-line treatment of RCC in which tivozanib demonstrated a significant improvement over sorafenib in the study’s primary endpoint of progression free survival. At the advisory meetings, AVEO provided data demonstrating that the discordance in overall survival (OS), the secondary endpoint of the study, was very likely attributable to the crossover design of the study. The final meeting minutes reflect that the Rapporteurs "did not see a ‘blocking issue’ with the OS trend" and that AVEO "clearly presented a credible story for the Rapporteurs to assess but one which would need to be supported with very careful reasoning." AVEO was also reminded that the Rapporteurs "cannot advise on [the] final outcome of the review."

"We are pleased that both the Rapporteur and Co-Rapporteur were supportive of an MAA filing for tivozanib in RCC using TIVO-1 as the pivotal study," said Michael Bailey, president and chief executive officer of AVEO. "We believe tivozanib may provide an important addition to the clinical armamentarium in the treatment of this disease. Based on our assessment of the economic and infrastructure requirements associated with filing an MAA and subsequently launching tivozanib in Europe, we are evaluating partnership opportunities to take tivozanib forward in this important market as we continue to prepare for a filing."